Marco Valerio Mariani1, Michele Magnocavallo2, Martina Straito2, Agostino Piro2, Paolo Severino2, Gino Iannucci3, Cristina Chimenti2, Massimo Mancone2, Domenico Giovanni Della Rocca4, Giovanni Battista Forleo5, Francesco Fedele2, Carlo Lavalle2. 1. Department of Cardiovascular, Respiratory, Nephrology, Anesthesiology and Geriatric Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. marcoval.mariani@gmail.com. 2. Department of Cardiovascular, Respiratory, Nephrology, Anesthesiology and Geriatric Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. 3. Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. 4. Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, TX, USA. 5. Department of Cardiology, Luigi Sacco Hospital, Milan, Italy.
Abstract
BACKGROUND: Direct oral anticoagulants (DOACs) are recommended as first-line anticoagulants in patients with atrial fibrillation (AF). However, in patients with cancer and AF the efficacy and safety of DOACs are not well established. OBJECTIVE: We performed a meta-analysis comparing available data regarding the efficacy and safety of DOACs vs vitamin K antagonists (VKAs) in cancer patients with non-valvular AF. METHODS: An online search of Pubmed and EMBASE libraries (from inception to May, 1 2020) was performed, in addition to manual screening. Nine studies were considered eligible for the meta-analysis involving 46,424 DOACs users and 182,797 VKA users. RESULTS: The use of DOACs was associated with reduced risks of systemic embolism or any stroke (RR 0.65; 95% CI 0.52-0.81; p 0.001), ischemic stroke (RR 0.84; 95% CI 0.74-0.95; p 0.007) and hemorrhagic stroke (RR 0.61; 95% CI 0.52-0.71; p 0.00001) as compared to VKA group. DOAC use was associated with significantly reduced risks of major bleeding (RR 0.68; 95% CI 0.50-0.92; p 0.01) and intracranial or gastrointestinal bleeding (RR 0.64; 95% CI 0.47-0.88; p 0.006). Compared to VKA, DOACs provided a non-statistically significant risk reduction of the outcomes major bleeding or non-major clinically relevant bleeding (RR 0.94; 95% CI 0.78-1.13; p 0.50) and any bleeding (RR 0.91; 95% CI 0.78-1.06; p 0.24). CONCLUSIONS: In comparison to VKA, DOACs were associated with a significant reduction of the rates of thromboembolic events and major bleeding complications in patients with AF and cancer. Further studies are needed to confirm our results.
BACKGROUND: Direct oral anticoagulants (DOACs) are recommended as first-line anticoagulants in patients with atrial fibrillation (AF). However, in patients with cancer and AF the efficacy and safety of DOACs are not well established. OBJECTIVE: We performed a meta-analysis comparing available data regarding the efficacy and safety of DOACs vs vitamin K antagonists (VKAs) in cancerpatients with non-valvular AF. METHODS: An online search of Pubmed and EMBASE libraries (from inception to May, 1 2020) was performed, in addition to manual screening. Nine studies were considered eligible for the meta-analysis involving 46,424 DOACs users and 182,797 VKA users. RESULTS: The use of DOACs was associated with reduced risks of systemic embolism or any stroke (RR 0.65; 95% CI 0.52-0.81; p 0.001), ischemic stroke (RR 0.84; 95% CI 0.74-0.95; p 0.007) and hemorrhagic stroke (RR 0.61; 95% CI 0.52-0.71; p 0.00001) as compared to VKA group. DOAC use was associated with significantly reduced risks of major bleeding (RR 0.68; 95% CI 0.50-0.92; p 0.01) and intracranial or gastrointestinal bleeding (RR 0.64; 95% CI 0.47-0.88; p 0.006). Compared to VKA, DOACs provided a non-statistically significant risk reduction of the outcomes major bleeding or non-major clinically relevant bleeding (RR 0.94; 95% CI 0.78-1.13; p 0.50) and any bleeding (RR 0.91; 95% CI 0.78-1.06; p 0.24). CONCLUSIONS: In comparison to VKA, DOACs were associated with a significant reduction of the rates of thromboembolic events and major bleeding complications in patients with AF and cancer. Further studies are needed to confirm our results.
Entities:
Keywords:
Atrial fibrillation; Cancer; Direct oral anticoagulants; Vitamin K antagonists
Authors: Christina L Fanola; Christian T Ruff; Sabina A Murphy; James Jin; Anil Duggal; Noe A Babilonia; Piyamitr Sritara; Michele F Mercuri; Pieter W Kamphuisen; Elliott M Antman; Eugene Braunwald; Robert P Giugliano Journal: J Am Heart Assoc Date: 2018-08-21 Impact factor: 5.501
Authors: Carlo Lavalle; Marco Valerio Mariani; Agostino Piro; Michele Magnocavallo; Giampaolo Vetta; Sara Trivigno; Giovanni Battista Forleo; Domenico Giovanni Della Rocca; Massimo Uguccioni; Vincenzo Russo; Francesco Summaria; Luca Di Lullo Journal: J Clin Med Date: 2022-06-04 Impact factor: 4.964
Authors: Cristina Chimenti; Carlo Lavalle; Michele Magnocavallo; Maria Alfarano; Marco Valerio Mariani; Federico Bernardini; Domenico Giovanni Della Rocca; Gioacchino Galardo; Paolo Severino; Luca Di Lullo; Fabio Miraldi; Francesco Fedele; Andrea Frustaci Journal: ESC Heart Fail Date: 2021-12-16
Authors: Shirin Ardeshirrouhanifard; Huijun An; Ravi K Goyal; Mukaila A Raji; Jodi B Segal; G Caleb Alexander; Hemalkumar B Mehta Journal: Pharmacotherapy Date: 2022-04-14 Impact factor: 6.251
Authors: Anna Falanga; Avi Leader; Chiara Ambaglio; Zsuzsa Bagoly; Giancarlo Castaman; Ismail Elalamy; Ramon Lecumberri; Alexander Niessner; Ingrid Pabinger; Sebastian Szmit; Alice Trinchero; Hugo Ten Cate; Bianca Rocca Journal: Hemasphere Date: 2022-07-13
Authors: Anne Gulbech Ording; Mette Søgaard; Flemming Skjøth; Erik Lerkevang Grove; Gregory Y H Lip; Torben Bjerregaard Larsen; Peter Brønnum Nielsen Journal: Res Pract Thromb Haemost Date: 2022-01-13